Loading...
Loading...
India's domperidone imports from FRANCE total $268 across 7 shipments from 4 foreign suppliers. JNTL CONSUMER HEALTH (FRANS) SAS leads with $125 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include JOHNSON & JOHNSON PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for domperidone โ a diversified sourcing base with multiple active suppliers from FRANCE.

JNTL CONSUMER HEALTH (FRANS) SAS is the leading Domperidone supplier from FRANCE to India, with import value of $125 across 2 shipments. The top 5 suppliers โ JNTL CONSUMER HEALTH (FRANS) SAS, VIATRIS SANTE, INPHARMASCI SAS, JANSSEN-CILAG โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | JNTL CONSUMER HEALTH (FRANS) SAS | $125 | 2 | 46.5% |
| 2 | VIATRIS SANTE | $119 | 1 | 44.2% |
| 3 | INPHARMASCI SAS | $16 | 3 | 6.1% |
| 4 | JANSSEN-CILAG | $9 | 1 | 3.2% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | JOHNSON & JOHNSON PRIVATE LIMITED | $133 | 3 | 49.7% |
| 2 | MYLAN LABORATORIES LIMITED | $119 | 1 | 44.2% |
| 3 | ATHENA DRUG DELIVERY SOLUTIONS PRIVATE LIMITED |
FRANCE โ India trade corridor intelligence
As of April 2026, the France to India shipping corridor remains active, with both sea and air freight options available. Sea freight typically takes approximately 30 days, while air freight is faster, averaging around 7 days. The majority of shipments are transported by sea (80%), with a smaller proportion by air (20%). There are no significant reports of port congestion at major Indian ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, or Mundra. Freight rates have remained stable, and the exchange rate between the Indian Rupee (INR) and the Euro has shown minimal fluctuation, ensuring predictable costs for importers.
India's recent import policies, including the PLI scheme, aim to boost domestic manufacturing and reduce reliance on imports. These initiatives may impact the volume of finished formulation imports, including those from France. Import substitution policies are being evaluated to identify areas where domestic production can meet market demand, potentially leading to a decrease in import dependency. Importers should monitor these policy developments to adapt their strategies accordingly.
| $16 |
| 3 |
| 6.1% |
India and France maintain a robust trade relationship, with ongoing discussions to enhance cooperation in various sectors, including pharmaceuticals. Negotiations for Free Trade Agreements (FTAs) and mutual recognition of Good Manufacturing Practices (GMP) are underway to facilitate smoother trade flows. These efforts aim to streamline regulatory processes and promote bilateral trade in the pharmaceutical sector. Stakeholders should stay informed about these developments to leverage potential opportunities.
To estimate the landed cost of importing finished pharmaceutical formulations containing Domperidone from France to India, consider the following components:
By summing these components, importers can determine the total landed cost per unit, which is essential for pricing strategies and profitability analysis.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Domperidone into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs possess a valid import license issued under Form 10 of the Drugs and Cosmetics Rules, 1945. Additionally, each product must be registered with CDSCO under Form 41, which serves as authorization for importation. Importers must also obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT) to facilitate customs clearance. The registration process involves submitting comprehensive data on the drug's safety, efficacy, and quality, including stability studies in accordance with ICH guidelines. The timeline for obtaining these approvals can vary, but it typically ranges from several months to over a year, depending on the complexity of the product and the efficiency of the regulatory bodies. For formulations under HS Code 30049039, specific requirements include detailed product dossiers, manufacturing licenses from the country of origin, and a No Objection Certificate (NOC) from the manufacturer authorizing the import. It's crucial to ensure that all documentation is current and complies with Indian regulations to avoid delays or rejections.
Imported pharmaceutical formulations containing Domperidone must undergo quality testing to ensure they meet Indian standards. CDSCO-approved laboratories conduct batch-wise testing, which includes verifying the Certificate of Analysis (CoA) provided by the manufacturer. Stability data, particularly in ICH Zone IV conditions, is essential to demonstrate the product's shelf-life and efficacy under Indian climatic conditions. The Indian Pharmacopoeia sets the standards for quality, purity, and strength. Upon arrival, customs drug inspectors perform port inspections to assess compliance with these standards. If a batch fails to meet the required criteria, it may be rejected, leading to potential financial losses and reputational damage for the importer. Therefore, ensuring that all imported batches comply with Indian quality standards is imperative for market acceptance and patient safety.
Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting pharmaceutical imports. Notably, the introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of finished formulation imports. Additionally, the CDSCO has streamlined procedures for the transfer of drugs manufactured in Special Economic Zones (SEZs) to the Domestic Tariff Area (DTA), emphasizing compliance with quality, safety, and efficacy standards. These changes aim to bolster domestic production capabilities and reduce dependency on imports, aligning with India's self-reliance initiatives. Importers should stay informed about these policy shifts to navigate the evolving regulatory landscape effectively.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Domperidone formulations to meet the demand for specific dosage forms and branded products not available domestically. The domestic market for Domperidone is substantial, with a total export value of $29.6 million across 493 exporters to 115 countries. However, certain specialized formulations, such as specific tablet strengths or combination products, may not be manufactured locally, necessitating imports. The reliance on imports is also influenced by factors like patent protections and the availability of advanced manufacturing technologies in the exporting countries. Understanding these dynamics is crucial for stakeholders aiming to navigate the Indian pharmaceutical market effectively.
The import of finished pharmaceutical formulations containing Domperidone (HS Code 30049039) into India is subject to a Basic Customs Duty (BCD) of 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is applicable. The Integrated Goods and Services Tax (IGST) is also levied, with the rate varying based on the specific product classification. There are no exemptions or preferential rates for imports from France under the Most Favored Nation (MFN) status. Importers should account for these duties and taxes when calculating the total landed cost of imported goods.
India sources finished Domperidone formulations from France due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized formulations. French manufacturers often offer patented or branded products that are not produced domestically, providing a competitive edge in the Indian market. While other countries like China, Germany, and the United States also export pharmaceutical products to India, France's reputation for quality and innovation makes it a preferred source for certain formulations. The French pharmaceutical sector's commitment to research and development further enhances its position in the global market.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished Domperidone formulations from France to access specialized dosage forms and branded products not available domestically. French manufacturers often provide patented formulations and advanced technologies that enhance the therapeutic efficacy of Domperidone. These imports cater to specific patient needs and market segments, ensuring a diverse and comprehensive product offering in the Indian market.
When compared to other sourcing countries like China, Germany, and the United States, France offers distinct advantages in terms of product quality, regulatory compliance, and innovation. French pharmaceutical products are renowned for their adherence to stringent quality standards and their ability to meet specific market demands. While other countries may offer competitive pricing, France's reputation for quality and reliability makes it a preferred choice for certain pharmaceutical imports.
Importing finished pharmaceutical formulations from France involves certain risks
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Domperidone suppliers from FRANCE to India include JNTL CONSUMER HEALTH (FRANS) SAS, VIATRIS SANTE, INPHARMASCI SAS. The leading supplier is JNTL CONSUMER HEALTH (FRANS) SAS with import value of $125 USD across 2 shipments. India imported Domperidone worth $268 USD from FRANCE in total across 7 shipments.
India imported Domperidone worth $268 USD from FRANCE across 7 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Domperidone sourced from FRANCE include JOHNSON & JOHNSON PRIVATE LIMITED, MYLAN LABORATORIES LIMITED, ATHENA DRUG DELIVERY SOLUTIONS PRIVATE LIMITED. The largest buyer is JOHNSON & JOHNSON PRIVATE LIMITED with $133 in imports across 3 shipments.
The total value of Domperidone imports from FRANCE to India is $268 USD, across 7 shipments and 4 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
7 Verified Shipments
4 suppliers, 3 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists